Literature DB >> 11027823

Induction of lymphocyte recruitment in the absence of a detectable immune response.

R G Windon1, P J Chaplin, L Beezum, A Coulter, R Cahill, W Kimpton, D Drane, M Pearse, A Sjölander, J M Tennent, J Y Scheerlinck.   

Abstract

Lymphocyte recruitment from blood into the lymph node is thought to be initiated by the presence of antigen. In this study, we have used lymphatic cannulation in sheep to demonstrate that the adjuvant ISCOMATRIX can induce dramatic lymph node activation in the absence of antigen. Consistent patterns of node shutdown (decreased output) and cell recruitment (increased output) with minimal blast cell responses were observed indicating that an antigen-specific immune response is not required. Production of IL-6, IL-8 and IFN-gamma, and the transient presence of red blood cells and neutrophils in the efferent lymph were associated with changes in efferent lymph cell trafficking. These early events may facilitate the screening of low frequency antigen-specific cells for binding to antigen and the subsequent amplification of the immune response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027823     DOI: 10.1016/s0264-410x(00)00148-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.

Authors:  Peter Duewell; Ulrich Kisser; Klaus Heckelsmiller; Sabine Hoves; Patrizia Stoitzner; Sandra Koernig; Adriana B Morelli; Björn E Clausen; Marc Dauer; Andreas Eigler; David Anz; Carole Bourquin; Eugene Maraskovsky; Stefan Endres; Max Schnurr
Journal:  J Immunol       Date:  2011-05-25       Impact factor: 5.422

2.  A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity.

Authors:  Murillo Silva; Yu Kato; Mariane B Melo; Ivy Phung; Brian L Freeman; Zhongming Li; Kangsan Roh; Jan W Van Wijnbergen; Hannah Watkins; Chiamaka A Enemuo; Brittany L Hartwell; Jason Y H Chang; Shuhao Xiao; Kristen A Rodrigues; Kimberly M Cirelli; Na Li; Sonya Haupt; Aereas Aung; Benjamin Cossette; Wuhbet Abraham; Swati Kataria; Raiza Bastidas; Jinal Bhiman; Caitlyn Linde; Nathaniel I Bloom; Bettina Groschel; Erik Georgeson; Nicole Phelps; Ayush Thomas; Julia Bals; Diane G Carnathan; Daniel Lingwood; Dennis R Burton; Galit Alter; Timothy P Padera; Angela M Belcher; William R Schief; Guido Silvestri; Ruth M Ruprecht; Shane Crotty; Darrell J Irvine
Journal:  Sci Immunol       Date:  2021-12-03

Review 3.  Selection of adjuvants for vaccines targeting specific pathogens.

Authors:  Indranil Sarkar; Ravendra Garg; Sylvia van Drunen Littel-van den Hurk
Journal:  Expert Rev Vaccines       Date:  2019-04-22       Impact factor: 5.217

4.  Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen.

Authors:  Jenny M Reimer; Karin H Karlsson; Karin Lövgren-Bengtsson; Sofia E Magnusson; Alexis Fuentes; Linda Stertman
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

5.  Mannosylated mucin-type immunoglobulin fusion proteins enhance antigen-specific antibody and T lymphocyte responses.

Authors:  Gustaf Ahlén; Lena Strindelius; Tomas Johansson; Anki Nilsson; Nathalie Chatzissavidou; Magnus Sjöblom; Ulrika Rova; Jan Holgersson
Journal:  PLoS One       Date:  2012-10-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.